Condition (MeSH)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
ClinicalTrials.gov lists 13 trials for Anti-N-Methyl-D-Aspartate Receptor Encephalitis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Anti-N-Methyl-D-Aspartate Receptor Encephalitis itself; the rest are tagged with a narrower condition beneath it.
When did Anti-N-Methyl-D-Aspartate Receptor Encephalitis trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2014 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Anti-N-Methyl-D-Aspartate Receptor Encephalitis trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 7 |
How many Anti-N-Methyl-D-Aspartate Receptor Encephalitis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Completed | 3 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Anti-N-Methyl-D-Aspartate Receptor Encephalitis? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 1 |
| Efgartigimod | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ofatumumab 300 | 1 |
| Repeated intravenous immunoglobulin/plasma exchange therapy | 1 |
| IA session | 1 |
| Taitacept | 1 |
| Ofatumumab combined with daratumumab | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Anti-N-Methyl-D-Aspartate Receptor Encephalitis? (25)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Assessment of long-term psychosocial outcomes in N-methyl-D-aspartate receptor encephalitis - the SAPIENCE study protocol. | BMC neurology | 2024 | Yes |
| Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders. | The Lancet. Neurology | 2022 | Yes |
| Clinical Significance of Delirium With Catatonic Signs in Patients With Neurological Disorders. | The Journal of neuropsychiatry and clinical neurosciences | 2022 | Yes |
| Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. | JAMA neurology | 2021 | Yes |
| Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. | Annals of neurology | 2021 | Yes |
Showing 5 of 25 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| NMDA receptor encephalitis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| NMDA receptor encephalitis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| NMDA receptor encephalitis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| NMDA receptor encephalitis | 217253 | Exact | Orphadata Science knowledge files, Product 1 |
| NMDA receptor encephalitis | 217253 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.